Skip to main content Skip to footer
HomeHome
 
  • Startseite
  • Patentrecherche

    Patentwissen

    Unsere Patentdatenbanken und Recherchetools

    Zur Übersicht 

    • Übersicht
    • Technische Information
      • Übersicht
      • Espacenet - Patentsuche
      • Europäischer Publikationsserver
      • EP-Volltextrecherche
    • Rechtliche Information
      • Übersicht
      • Europäisches Patentregister
      • Europäisches Patentblatt
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Übersicht
      • PATSTAT
      • IPscore
      • Technologieanalyseberichte
    • Daten
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
      • Web-Dienste
      • Datenbestände, Codes und Statistiken
    • Technologieplattformen
      • Übersicht
      • Kunststoffe im Wandel
      • Innovationen im Wassersektor
      • Innovationen im Weltraumsektor
      • Technologien zur Bekämpfung von Krebs
      • Technologien zur Brandbekämpfung
      • Saubere Energietechnologien
      • Kampf gegen Corona
    • Nützliche Informationsquellen
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
      • Patentinformation aus Asien
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
    Bild
    Plastics in Transition

    Technologieanalysebericht zur Plastikabfallwirtschaft

  • Anmelden eines Patents

    Anmelden eines Patents

    Praktische Informationen über Anmelde- und Erteilungsverfahren.

    Zur Übersicht 

    • Übersicht
    • Europäischer Weg
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
      • Nationale Validierung
      • Antrag auf Erstreckung/Validierung
    • Internationaler Weg (PCT)
      • Übersicht
      • Euro-PCT-Leitfaden: PCT-Verfahren im EPA
      • Beschlüsse und Mitteilungen des EPA
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
      • Schulungen und Veranstaltungen
    • Nationale Anmeldungen
    • Zugelassenen Vertreter suchen
    • MyEPO Services
      • Übersicht
      • Unsere Dienste verstehen
      • Zugriff erhalten
      • Bei uns einreichen
      • Akten interaktiv bearbeiten
      • Verfügbarkeit der Online-Dienste
    • Formblätter
      • Übersicht
      • Prüfungsantrag
    • Gebühren
      • Übersicht
      • Europäische Gebühren (EPÜ)
      • Internationale Gebühren (PCT)
      • Einheitspatentgebühren (UP)
      • Gebührenzahlung und Rückerstattung
      • Warnung

    UP

    Erfahren Sie, wie das Einheitspatent Ihre IP-Strategie verbessern kann

  • Recht & Praxis

    Recht & Praxis

    Europäisches Patentrecht, Amtsblatt und andere Rechtstexte

    Zur Übersicht 

    • Übersicht
    • Rechtstexte
      • Übersicht
      • Europäisches Patentübereinkommen
      • Amtsblatt
      • Richtlinien
      • Erstreckungs-/ Validierungssyste
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
      • Système du brevet unitaire
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
    Bild
    Law and practice scales 720x237

    Informieren Sie sich über die wichtigsten Aspekte ausgewählter BK-Entscheidungen in unseren monatlichen „Abstracts of decisions“

  • Neues & Veranstaltungen

    Neues & Veranstaltungen

    Aktuelle Neuigkeiten, Podcasts und Veranstaltungen.

    Zur Übersicht 

     

    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Übersicht
      • Die bedeutung von morgen
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Finalisten kennen
      • Nominierungen
      • European Inventor Network
      • Preisverleihung 2024
    • Young Inventor Prize
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die jury
      • Die Welt, neu gedacht
    • Pressezentrum
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Innovation und Patente im Blickpunkt
      • Übersicht
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
      • Zukunft der Medizin
      • Werkstoffkunde
      • Mobile Kommunikation: Das große Geschäft mit kleinen Geräten
      • Biotechnologiepatente
      • Patentklassifikation
      • Digitale Technologien
      • Die Zukunft der Fertigung
      • Books by EPO experts
    • Podcast "Talk innovation"

    Podcast

    Von der Idee zur Erfindung: unser Podcast informiert Sie topaktuell in Sachen Technik und IP

  • Lernen

    Lernen

    Europäische Patentakademie – unser Kursportal für Ihre Fortbildung

    Zur Übersicht 

    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Übersicht
      • Schulungsaktivitäten
      • Lernpfade
    • EEP und EPVZ
      • Übersicht
      • EEP – Europäische Eignungsprüfung
      • EPVZ – Europäisches Patentverwaltungszertifikat
      • CSP – Programm zur Unterstützung von Bewerbern
    • Lernmaterial nach Interesse
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Durchsetzung
    • Lernmaterial nach Profil
      • Übersicht
      • Geschäftswelt und IP
      • EEP und EPVZ Bewerber
      • Justiz
      • Nationale Ämter und IP-Behörden
      • Patentanwaltskanzleien
      • Lehre und Forschung
    Bild
    Patent Academy catalogue

    Werfen Sie einen Blick auf das umfangreiche Lernangebot im Schulungskatalog der Europäischen Patentakademie

  • Über uns

    Über uns

    Erfahren Sie mehr über Tätigkeit, Werte, Geschichte und Vision des EPA

    Zur Übersicht 

    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre Europäisches Patentübereinkommen
      • Übersicht
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten der Europäischen Patentorganisation
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Übersicht
      • Kommuniqués
      • Kalender
      • Dokumente und Veröffentlichungen
      • Der Verwaltungsrat der Europäischen Patentorganisation
    • Unsere Grundsätze und Strategie
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategischer Plan 2028
      • Auf dem Weg zu einer neuen Normalität
    • Führung und Management
      • Übersicht
      • Präsident António Campinos
      • Managementberatungsausschuss
    • Sustainability at the EPO
      • Übersicht
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Dienste & Aktivitäten
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
      • Nutzerkonsultation
      • Europäische und internationale Zusammenarbeit
      • Europäische Patentakademie
      • Chefökonom
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Übersicht
      • Akteure im Innovationsbereich
      • Politisches Umfeld und Finanzierung
      • Tools
      • Über die Beobachtungsstelle
    • Beschaffung
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Nachhaltiger Beschaffungsstandard
      • Registrierung zum eTendering und elektronische Signaturen
      • Beschaffungsportal
      • Rechnungsstellung
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Transparenzportal
      • Übersicht
      • Allgemein
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • Die Geschichte des EPA
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Die EPA Kunstsammlung
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
      • "Lange Nacht"
    Bild
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Verfolgen Sie die neuesten Technologietrends mit unserem Patentindex

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • Sind Patente Neuland für Sie?
  • Sind Patente Neuland für Sie?
    • Go back
    • Patente für Ihr Unternehmen?
    • Warum ein Patent?
    • Was ist Ihre zündende Idee?
    • Sind Sie bereit?
    • Darum geht es
    • Der Weg zum Patent
    • Ist es patentierbar?
    • Ist Ihnen jemand zuvorgekommen?
    • Patentquiz
    • Video zum Einheitspatent
  • Patentrecherche
    • Go back
    • Übersicht
    • Technische Information
      • Go back
      • Übersicht
      • Espacenet - Patentsuche
        • Go back
        • Übersicht
        • Datenbanken der nationalen Ämter
        • Global Patent Index (GPI)
        • Versionshinweise
      • Europäischer Publikationsserver
        • Go back
        • Übersicht
        • Versionshinweise
        • Konkordanzliste für Euro-PCT-Anmeldungen
        • EP-Normdatei
        • Hilfe
      • EP-Volltextrecherche
    • Rechtliche Information
      • Go back
      • Übersicht
      • Europäisches Patentregister
        • Go back
        • Übersicht
        • Versionshinweise: Archiv
        • Dokumentation zu Register
          • Go back
          • Übersicht
          • Datenverfügbarkeit für Deep Links
          • Vereinigtes Register
          • Ereignisse im Register
      • Europäisches Patentblatt
        • Go back
        • Übersicht
        • Patentblatt herunterladen
        • Recherche im Europäischen Patentblatt
        • Hilfe
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Go back
      • Übersicht
      • PATSTAT
      • IPscore
        • Go back
        • Versionshinweise
      • Technologieanalyseberichte
    • Daten
      • Go back
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
        • Go back
        • Übersicht
        • Manuals
        • Sequenzprotokolle
        • Nationale Volltextdaten
        • Daten des Europäischen Patentregisters
        • Weltweite bibliografische Daten des EPA (DOCDB)
        • EP-Volltextdaten
        • Weltweite Rechtsereignisdaten des EPA (INPADOC)
        • Bibliografische Daten von EP-Dokumenten (EBD)
        • Entscheidungen der Beschwerdekammern des EPA
      • Web-Dienste
        • Go back
        • Übersicht
        • Open Patent Services (OPS)
        • Europäischer Publikationsserver (Web-Dienst)
      • Datenbestände, Codes und Statistiken
        • Go back
        • Wöchentliche Aktualisierungen
        • Regelmäßige Aktualisierungen
    • Technologieplattformen
      • Go back
      • Kunststoffe im Wandel
        • Go back
        • Overview
        • Verwertung von Plastikabfällen
        • Recycling von Plastikabfällen
        • Alternative Kunststoffe
      • Übersicht
      • Innovative Wassertechnologien
        • Go back
        • Overview
        • Sauberes Wasser
        • Schutz vor Wasser
      • Innovationen im Weltraumsektor
        • Go back
        • Übersicht
        • Kosmonautik
        • Weltraumbeobachtung
      • Technologien zur Bekämpfung von Krebs
        • Go back
        • Übersicht
        • Prävention und Früherkennung
        • Diagnostik
        • Therapien
        • Wohlergehen und Nachsorge
      • Technologien zur Brandbekämpfung
        • Go back
        • Übersicht
        • Branderkennung und -verhütung
        • Feuerlöschen
        • Schutzausrüstung
        • Technologien für die Sanierung nach Bränden
      • Saubere Energietechnologien
        • Go back
        • Übersicht
        • Erneuerbare Energien
        • CO2-intensive Industrien
        • Energiespeicherung und andere Enabling-Technologien
      • Kampf gegen Corona
        • Go back
        • Übersicht
        • Impfstoffe und Therapeutika
          • Go back
          • Übersicht
          • Impfstoffe
          • Übersicht über Therapieansätze für COVID-19
          • Kandidaten für antivirale Therapeutika
          • Nukleinsäuren zur Behandlung von Coronavirus-Infektionen
        • Diagnose und Analyse
          • Go back
          • Übersicht
          • Protein-und Nukleinsäure-Nachweis
          • Analyseprotokolle
        • Informatik
          • Go back
          • Übersicht
          • Bioinformatik
          • Medizinische Informatik
        • Technologien für die neue Normalität
          • Go back
          • Übersicht
          • Geräte, Materialien und Ausrüstung
          • Verfahren, Maßnahmen und Aktivitäten
          • Digitale Technologien
        • Erfinderinnen und Erfinder gegen das Coronavirus
    • Nützliche Informationsquellen
      • Go back
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
        • Go back
        • Übersicht
        • Grundlegende Definitionen
        • Patentklassifikation
          • Go back
          • Übersicht
          • Gemeinsame Patentklassifikation
        • Patentfamilien
          • Go back
          • Übersicht
          • Einfache DOCDB Patentfamilie
          • Erweiterte INPADOC Patentfamilie
        • Daten zu Rechtsstandsereignissen
          • Go back
          • Übersicht
          • INPADOC-Klassifikationssystem
      • Patentinformation aus Asien
        • Go back
        • Übersicht
        • China (CN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinesisch-Taipei (TW)
          • Go back
          • Übersicht
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Indien (IN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russische Föderation (RU)
          • Go back
          • Übersicht
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
  • Anmelden eines Patents
    • Go back
    • Übersicht
    • Europäischer Weg
      • Go back
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
        • Go back
        • Kalender der mündlichen Verhandlungen
          • Go back
          • Kalender der mündlichen Verhandlungen
          • Technische Richtlinien
          • Zugang für die Öffentlichkeit zum Beschwerdeverfahren
          • Zugang für die Öffentlichkeit zum Einspruchsverfahren
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
        • Go back
        • Einheitspatent
          • Go back
          • Übersicht
          • Rechtlicher Rahmen
          • Wesentliche Merkmale
          • Beantragung eines Einheitspatents
          • Kosten eines Einheitspatents
          • Übersetzungsregelungen und Kompensationssystem
          • Starttermin
          • Introductory brochures
        • Übersicht
        • Einheitliches Patentgericht
      • Nationale Validierung
      • Erstreckungs- /Validierungsantrag
    • Internationaler Weg
      • Go back
      • Übersicht
      • Euro-PCT-Leitfaden
      • Eintritt in die europäische Phase
      • Beschlüsse und Mitteilungen
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
        • Go back
        • Programm "Patent Prosecution Highway" (PPH) - Übersicht
      • PCT: Schulungen und Veranstaltungen
    • Nationaler Weg
    • MyEPO Services
      • Go back
      • Übersicht
      • Unsere Dienste verstehen
        • Go back
        • Übersicht
        • Exchange data with us using an API
          • Go back
          • Versionshinweise
      • Zugriff erhalten
        • Go back
        • Übersicht
        • Versionshinweise
      • Bei uns einreichen
        • Go back
        • Bei uns einreichen
        • Wenn unsere Dienste für die Online-Einreichung ausfallen
        • Versionshinweise
      • Akten interaktiv bearbeiten
        • Go back
        • Versionshinweise
      • Verfügbarkeit der Online-Dienste
    • Gebühren
      • Go back
      • Übersicht
      • Europäische Gebühren (EPÜ)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Internationale Gebühren (PCT)
        • Go back
        • Ermäßigung der Gebühren
        • Gebühren für internationale Anmeldungen
        • Beschlüsse und Mitteilungen
        • Übersicht
      • Einheitspatentgebühren (UP)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Gebührenzahlung und Rückerstattung
        • Go back
        • Übersicht
        • Zahlungsarten
        • Erste Schritte
        • FAQs und sonstige Anleitungen
        • Technische Informationen für Sammelzahlungen
        • Beschlüsse und Mitteilungen
        • Versionshinweise
      • Warnung
    • Formblätter
      • Go back
      • Prüfungsantrag
      • Übersicht
    • Zugelassenen Vertreter suchen
  • Recht & Praxis
    • Go back
    • Übersicht
    • Rechtstexte
      • Go back
      • Übersicht
      • Europäisches Patentübereinkommen
        • Go back
        • Übersicht
        • Archiv
          • Go back
          • Übersicht
          • Dokumentation zur EPÜ-Revision 2000
            • Go back
            • Übersicht
            • Diplomatische Konferenz für die Revision des EPÜ
            • "Travaux préparatoires" (Vorarbeiten)
            • Neufassung
            • Übergangsbestimmungen
            • Ausführungsordnung zum EPÜ 2000
            • Gebührenordnung
            • Ratifikationen und Beitritte
          • Travaux Préparatoires EPÜ 1973
      • Amtsblatt
      • Richtlinien
        • Go back
        • Übersicht
        • EPÜ Richtlinien
        • PCT-EPA Richtlinien
        • Richtlinien für das Einheitspatent
        • Überarbeitung der Richtlinien
        • Ergebnisse der Konsultation
        • Zusammenfassung der Nutzerbeiträge
        • Archiv
      • Erstreckungs-/Validierungssystem
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
        • Go back
        • Übersicht
        • Archiv
      • Einheitspatentsystem
        • Go back
        • Travaux préparatoires to UP and UPC
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Go back
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Go back
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Go back
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
  • Neues & Veranstaltungen
    • Go back
    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Go back
      • The meaning of tomorrow
      • Übersicht
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Erfinder kennen
      • Nominierungen
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • Preisverleihung 2024
    • Young Inventors Prize
      • Go back
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die Jury
      • Die Welt, neu gedacht
      • Preisverleihung 2025
    • Pressezentrum
      • Go back
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
        • Go back
        • Übersicht
        • Europäisches Patentamt
        • Fragen und Antworten zu Patenten im Zusammenhang mit dem Coronavirus
        • Fragen und Antworten zu Pflanzenpatenten
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Im Blickpunkt
      • Go back
      • Übersicht
      • Wasserbezogene Technologien
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Übersicht
        • CodeFest 2024 zu generativer KI
        • Codefest 2023 zu grünen Kunststoffen
      • Green tech in focus
        • Go back
        • Übersicht
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
        • Go back
        • Weltraumtechnologie und Patente
        • Übersicht
      • Gesundheit
        • Go back
        • Übersicht
        • Medizintechnik und Krebs
        • Personalised medicine
      • Werkstoffkunde
        • Go back
        • Übersicht
        • Nanotechnologie
      • Mobile Kommunikation
      • Biotechnologie
        • Go back
        • Rot, weiß oder grün
        • Übersicht
        • Die Rolle des EPA
        • Was ist patentierbar?
        • Biotechnologische Erfindungen und ihre Erfinder
      • Patentklassifikation
        • Go back
        • Übersicht
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Übersicht
          • External partners
          • Updates on Y02 and Y04S
      • Digitale Technologien
        • Go back
        • Übersicht
        • Über IKT
        • Hardware und Software
        • Künstliche Intelligenz
        • Vierte Industrielle Revolution
      • Additive Fertigung
        • Go back
        • Übersicht
        • Die additive Fertigung
        • Innovation durch AM
      • Books by EPO experts
    • Podcast
  • Lernen
    • Go back
    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Go back
      • Übersicht
      • Schulungsaktivitäten: Arten und Formate
      • Lernpfade
    • EEP und EPVZ
      • Go back
      • Übersicht
      • EEP – Europäische Eignungsprüfung
        • Go back
        • Übersicht
        • Compendium
          • Go back
          • Übersicht
          • Aufgabe F
          • Aufgabe A
          • Aufgabe B
          • Aufgabe C
          • Aufgabe D
          • Vorprüfung
        • Erfolgreiche Bewerber
        • Archiv
      • EPVZ – Europäisches Patentverwaltungszertifikat
      • CSP – Programm zur Unterstützung von Bewerbern
    • Angebot für bestimmte Interessengebiete
      • Go back
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Patentdurchsetzung und Streitregelung
    • Angebot für bestimmte Zielgruppen
      • Go back
      • Übersicht
      • Geschäftswelt und IP
        • Go back
        • Übersicht
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Fallstudien zum Technologietransfer
          • Fallstudien zu wachstumsstarken Technologien
        • Inventor's handbook
          • Go back
          • Übersicht
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Übersicht
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Übersicht
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EEP und EPVZ Bewerber
        • Go back
        • Übersicht
        • Denkaufgaben zu Aufgabe F
        • Tägliche Fragen zur Aufgabe D
        • Europäische Eignungsprüfung - Leitfaden zur Vorbereitung
        • EPVZ
      • Richter, Anwälte und Staatsanwälte
        • Go back
        • Übersicht
        • Compulsory licensing in Europe
        • Die Zuständigkeit europäischer Gerichte bei Patentstreitigkeiten
      • Nationale Ämter und IP-Behörden
        • Go back
        • Übersicht
        • Lernpfad für Patentprüfer der nationalen Ämter
        • Lernpfad für Formalsachbearbeiter und Paralegals
      • Patentanwaltskanzleien
      • Hochschulen, Forschungseinrichtungen und Technologietransferstellen
        • Go back
        • Übersicht
        • Modularer IP-Ausbildungsrahmen (MIPEF)
        • Programm "Pan-European-Seal für junge Fachkräfte"
          • Go back
          • Übersicht
          • Für Studierende
          • Für Hochschulen
            • Go back
            • Übersicht
            • IP-Schulungsressourcen
            • Hochschulmitgliedschaften
          • Unsere jungen Fachkräfte
          • Beruflicher Entwicklungsplan
        • Akademisches Forschungsprogramm (ARP)
          • Go back
          • Übersicht
          • Abgeschlossene Forschungsprojekte
          • Laufende Forschungsprojekte
        • IP Teaching Kit
          • Go back
          • Übersicht
          • Download modules
        • Handbuch für die Gestaltung von IP-Kursen
        • PATLIB Wissenstransfer nach Afrika
          • Go back
          • Die PATLIB-Initiative "Wissenstransfer nach Afrika" (KT2A)
          • KT2A-Kernaktivitäten
          • Erfolgsgeschichte einer KT2A-Partnerschaft: PATLIB Birmingham und Malawi University of Science and Technology
  • Über uns
    • Go back
    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre EPÜ
      • Go back
      • Official celebrations
      • Übersicht
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Go back
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten
        • Go back
        • Übersicht
        • Mitgliedstaaten sortiert nach Beitrittsdatum
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Go back
      • Übersicht
      • Kommuniqués
        • Go back
        • 2024
        • Übersicht
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Kalender
      • Dokumente und Veröffentlichungen
        • Go back
        • Übersicht
        • Dokumente des Engeren Ausschusses
      • Verwaltungsrat
        • Go back
        • Übersicht
        • Zusammensetzung
        • Vertreter
        • Geschäftsordnung
        • Kollegium der Rechnungsprüfer
        • Sekretariat
        • Nachgeordnete Organe
    • Grundsätze
      • Go back
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategieplan 2028
        • Go back
        • Treiber 1: Personal
        • Treiber 2: Technologien
        • Treiber 3: Qualitativ hochwertige Produkte und Dienstleistungen
        • Treiber 4: Partnerschaften
        • Treiber 5: Finanzielle Nachhaltigkeit
      • Auf dem Weg zu einer neuen Normalität
      • Datenschutzerklärung
    • Führung und Management
      • Go back
      • Übersicht
      • Über den Präsidenten
      • Managementberatungsausschuss
    • Nachhaltigkeit beim EPA
      • Go back
      • Overview
      • Umwelt
        • Go back
        • Overview
        • Inspirierende Erfindungen für die Umwelt
      • Soziales
        • Go back
        • Overview
        • Inspirierende soziale Erfindungen
      • Governance und finanzielle Nachhaltigkeit
    • Beschaffung
      • Go back
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Veröffentlichungen des Dynamischen Beschaffungssystems
      • Nachhaltiger Beschaffungsstandard
      • Über eTendering
      • Rechnungsstellung
      • Beschaffungsportal
        • Go back
        • Übersicht
        • Elektronische Signatur von Verträgen
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Dienste & Aktivitäten
      • Go back
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
        • Go back
        • Übersicht
        • Grundlagen
          • Go back
          • Übersicht
          • Europäisches Patentübereinkommen
          • Richtlinien für die Prüfung
          • Unsere Bediensteten
        • Qualität ermöglichen
          • Go back
          • Übersicht
          • Stand der Technik
          • Klassifikationssystem
          • Tools
          • Qualitätssicherung
        • Produkte & Dienstleistungen
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
          • Fortlaufende Verbesserung
        • Qualität durch Netzwerke
          • Go back
          • Übersicht
          • Nutzerengagement
          • Zusammenarbeit
          • Befragung zur Nutzerzufriedenheit
          • Stakeholder-Qualitätssicherungspanels
        • Charta für Patentqualität
        • Qualitätsaktionsplan
        • Qualitäts-Dashboard
        • Statistik
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
        • Integriertes Management beim EPA
      • Charta unserer Kundenbetreuung
      • Nutzerkonsultation
        • Go back
        • Übersicht
        • Ständiger Beratender Ausschuss beim EPA
          • Go back
          • Übersicht
          • Ziele
          • Der SACEPO und seine Arbeitsgruppen
          • Sitzungen
          • Bereich für Delegierte
        • Befragungen
          • Go back
          • Übersicht
          • Methodik
          • Recherche
          • Sachprüfung, abschließende Aktionen und Veröffentlichung
          • Einspruch
          • Formalprüfung
          • Kundenbetreuung
          • Einreichung
          • Key Account Management (KAM)
          • EPA-Website
          • Archiv
      • Europäische und internationale Zusammenarbeit
        • Go back
        • Übersicht
        • Zusammenarbeit mit den Mitgliedstaaten
          • Go back
          • Übersicht
        • Bilaterale Zusammenarbeit mit Nichtmitgliedstaaten
          • Go back
          • Übersicht
          • Validierungssystem
          • Programm für verstärkte Partnerschaft
        • Internationale Organisationen, Trilaterale und IP5
        • Zusammenarbeit mit internationalen Organisationen außerhalb des IP-Systems
      • Europäische Patentakademie
        • Go back
        • Übersicht
        • Partner
      • Chefökonom
        • Go back
        • Übersicht
        • Wirtschaftliche Studien
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Go back
      • Übersicht
      • Innovation gegen Krebs
      • Akteure im Innovationsbereich
        • Go back
        • Übersicht
        • Start-ups und KMU
      • Politisches Umfeld und Finanzierung
        • Go back
        • Übersicht
        • Programm zur Innovationsfinanzierung
          • Go back
          • Übersicht
          • Unsere Studien zur Innovationsfinanzierung
          • EPA-Initiativen für Patentanmelder/innen
          • Programm zur Innovationsfinanzierung
        • Patente und Normen
          • Go back
          • Übersicht
          • Publikationen
          • Patent standards explorer
      • Tools
        • Go back
        • Übersicht
        • Deep Tech Finder
      • Über die Beobachtungsstelle
        • Go back
        • Übersicht
        • Arbeitsplan
    • Transparency portal
      • Go back
      • Übersicht
      • Allgemein
        • Go back
        • Übersicht
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Übersicht
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Go back
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • Geschichte
      • Go back
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Kunstsammlung
      • Go back
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Frühere Ausstellungen
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Lange Nacht"
  • Beschwerdekammern
    • Go back
    • Übersicht
    • Entscheidungen der Beschwerdekammern
      • Go back
      • Neue Entscheidungen
      • Übersicht
      • Ausgewählte Entscheidungen
    • Mitteilungen der Beschwerdekammern
    • Verfahren
    • Mündliche Verhandlungen
    • Über die Beschwerdekammern
      • Go back
      • Übersicht
      • Präsident der Beschwerdekammern
      • Große Beschwerdekammer
        • Go back
        • Übersicht
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technische Beschwerdekammern
      • Juristische Beschwerdekammer
      • Beschwerdekammer in Disziplinarangelegenheiten
      • Präsidium
        • Go back
        • Übersicht
    • Verhaltenskodex
    • Geschäftsverteilungsplan
      • Go back
      • Übersicht
      • Technical boards of appeal by IPC in 2025
      • Archiv
    • Jährliche Liste der Verfahren
    • Mitteilungen
    • Jahresberichte
      • Go back
      • Übersicht
    • Veröffentlichungen
      • Go back
      • Abstracts of decisions
    • Rechtsprechung der Beschwerdekammern
      • Go back
      • Übersicht
      • Archiv
  • Service & Unterstützung
    • Go back
    • Übersicht
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
      • Go back
      • Übersicht
    • FAQ
      • Go back
      • Übersicht
    • Veröffentlichungen
    • Bestellung
      • Go back
      • Patentwissen – Produkte und Dienste
      • Übersicht
      • Allgemeine Geschäftsbedingungen
        • Go back
        • Übersicht
        • Patentinformationsprodukte
        • Massendatensätze
        • Open Patent Services (OPS)
        • Leitfaden zur fairen Nutzung
    • Verfahrensbezogene Mitteilungen
    • Nützliche Links
      • Go back
      • Übersicht
      • Patentämter der Mitgliedstaaten
      • Weitere Patentämter
      • Verzeichnisse von Patentvertretern
      • Patentdatenbanken, Register und Patentblätter
      • Haftungsausschluss
    • Aboverwaltung
      • Go back
      • Übersicht
      • Anmelden
      • Einstellungen verwalten
      • Abmelden
    • Veröffentlichungen
      • Go back
      • Übersicht
      • Möglichkeiten der Einreichung
      • Standorte
    • Offizielle Feiertage
    • Glossar
    • RSS-Feeds
Board of Appeals
Decisions

Recent decisions

Übersicht
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Startseite
  2. Node
  3. T 1991/17 (Bone mass increase by inducing osteogenesis/ORIENTAL YEAST) 05-10-2020
Facebook X Linkedin Email

T 1991/17 (Bone mass increase by inducing osteogenesis/ORIENTAL YEAST) 05-10-2020

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2020:T199117.20201005
Datum der Entscheidung:
05 October 2020
Aktenzeichen
T 1991/17
Antrag auf Überprüfung von
-
Anmeldenummer
08765502.3
IPC-Klasse
A61K45/00
A61K38/00
A61P19/02
A61P19/08
A61P19/10
C07K14/705
C12Q1/02
G01N33/15
G01N33/50
Verfahrenssprache
EN
Verteilung
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download und weitere Informationen:

Entscheidung in EN 470.27 KB
Alle Dokumente zum Beschwerdeverfahren finden Sie im Europäisches Patentregister
Bibliografische Daten verfügbar in:
EN
Fassungen
Nicht veröffentlicht
Bezeichnung der Anmeldung

NOVEL BONE MASS INCREASING AGENT

Name des Anmelders
Oriental Yeast Co., Ltd.
Name des Einsprechenden
Bettenhausen, Berthold
Kammer
3.3.01
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention 054 (2007)
European Patent Convention 083 (2007)
Rules of procedure of the Boards of Appeal 013(2) (2020)
Schlagwörter

Sufficiency of disclosure - main request (no)

Sufficiency of disclosure - undue burden

Novelty - auxiliary requests 1 and 3 (no)

Admission of auxiliary requests 2 and 4 (no)

Orientierungssatz
-
Angeführte Entscheidungen
T 1642/06
T 0836/01
G 0002/08
Anführungen in anderen Entscheidungen
-

Summary of Facts and Submissions

I. European patent No. EP 2 165 716 was opposed under Article 100(a), (b) and (c) EPC on the grounds that the claimed subject-matter lacked novelty and an inventive step, was not disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art, and extended beyond the content of the application as filed.

II. The following documents, cited during the opposition and appeal proceedings, are referred to below:

(4) Hofbauer et al., JAMA, 2004, 292(4), 490-495

(5) Sordillo et al., Cancer (Supplement), 2003, 97(3), 802-812

(6) Kostenuik et al., Curr. Pharm. Des, 2001, 7, 613-635

(7) Body et al., Cancer (Supplement), 2003, 97(3), 887-892

(8) WO03/002713

(9) WO03/086289

(10) McClung et al., N. Engl. J. Med., 2006, 354(8), 821-831

(11) Aoki et al., J. Clin. Invest., 2006, 116(6), 1525-1534

(12) Spreafico et al., J. Cell. Biochem, 2006, 98, 1007-1020

(13) Bekker et al., J. Bone Miner. Res., 2001, 16(2), 348-360

(15) Chavassieux et al., Endocr. Rev., 2007, 28(2), 151-164

(16) D.W. Dempster, "Principles of Bone Biology", 3rd edition, Academic Press, Inc., 2008, 447-463

(17) McClung et al., N. Engl. J. Med., 2014, 370(5), 412-420

(18) Geusens, RMD Open, 2015, 1 (Suppl 1), 1-5

(19) C.J. Rosen, "Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th edition, John Wiley & Sons, Inc., 2013, 428-433

(30) WO2015/125922

(30b) English translation of document (30), submitted on 17 November 2017, 50 pages

(31) Chikazu et al., J. Bone Miner. Res., 2002, 17(8), 1430-1440

(32) Tamura et al., J. Bone Miner.Res., 2001, 16(10), 1772-1779

(33) Ura et al., Endocr. J., 2000, 47(3), 293-302

(34) Padhi et al., J. Bone Miner. Res., 2011, 26(1), 19-26

III. In the course of the opposition proceedings, the patent proprietor requested that the opposition be rejected and submitted auxiliary requests 1 to 9, all filed on 8 March 2017.

During the oral proceedings before the opposition division, the proprietor withdrew its main request and auxiliary requests 1 to 6. Former auxiliary request 7 was made the new main request. Former auxiliary requests 8 and 9 were renumbered 1 and 2 respectively.

IV. The opposition division came to the conclusion that the main request fulfilled the requirements of the EPC.

V. The opponent filed an appeal. It submitted document (30b).

VI. With its reply the respondent (patent proprietor) submitted auxiliary requests 1 to 3 and documents (31) to (34).

VII. The board issued a communication pursuant to Article 15(1) RPBA, identifying crucial issues in the discussion of sufficiency of disclosure and novelty.

VIII. Oral proceedings before the board took place on 5 October 2020.

In the course of the oral proceedings, the respondent filed two new auxiliary requests. The filing of new auxiliary request 2 led to renumbering of the subsequent auxiliary requests. New auxiliary request 4 replaced former auxiliary request 4 (submitted as auxiliary request 3 with the reply to the statement of grounds of appeal). Claim 1 of each of the requests in the proceedings is reproduced below.

Claim 1 of the main request reads:

"1. A compound for use in the treatment or prevention of bone metabolic diseases associated with osteopenia by inducing osteogenesis, which is either:

(i) a compound that acts on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts, wherein the compound is selected from the group consisting of:

RANK,

a variant or fragment peptide of RANK,

an anti-RANKL antibody or a functional fragment thereof; or

(ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16."

Claim 1 of auxiliary request 1 reads:

"1. A compound for use in the treatment or prevention of bone metabolic diseases associated with osteopenia by inducing osteogenesis, which is either:

(i) a compound that acts on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts, wherein the compound is selected from the group consisting of:

RANK,

a fragment peptide of RANK,

a peptide consisting of the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16,

a fusion protein of a peptide comprising the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16 and GST or the Fc region of IgG1,

an anti-RANKL antibody or a functional fragment thereof; or

(ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16."

Claim 1 of auxiliary request 2 (filed during oral proceedings before the board) reads:

"1. A compound for use in the treatment or prevention of bone metabolic diseases associated with osteopenia by inducing osteogenesis, which is

a compound that acts on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts, wherein the compound is

an anti-RANKL antibody or a functional fragment thereof."

Claim 1 of auxiliary request 3 (filed as auxiliary request 2 with the reply to the grounds of appeal) reads:

"1. A compound for use in the treatment or prevention of bone metabolic diseases associated with osteopenia by inducing osteogenesis, which is either:

(i) a compound that acts on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts, wherein the compound is selected from the group consisting of:

RANK,

a peptide consisting of the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16,

a fusion protein of a peptide comprising the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16 and GST or the Fc region of IgG1,

an anti-RANKL antibody or a functional fragment thereof; or

(ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 7 or SEQ ID NO: 16."

Claim 1 of auxiliary request 4 (filed during oral proceedings before the board) reads as follows:

"1. A compound for use in the treatment or prevention of bone metabolic diseases associated with osteopenia by inducing osteogenesis, which is

a compound that acts on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts, wherein the compound is

an anti-RANKL antibody or a functional fragment thereof, and wherein the ability to promote differentiation or proliferation is based on an increase in the alkaline phosphatase activity of the cells."

IX. The arguments of the appellant (opponent), insofar as they are relevant for the present decision, may be summarised as follows.

Main request - sufficiency of disclosure

The application as filed did not show the suitability of the claimed compounds for the claimed therapeutic application over the full scope of claim 1 of the main request. In particular, the data of the patent in suit did not provide evidence of the induction of osteogenesis by all claimed compounds. Data on alkaline phosphatase activity were not suitable for showing that osteogenesis was induced, since no clear link between increased alkaline phosphatase activity and the treatment of osteopenia by osteogenesis had been established. Furthermore, the term "variant of RANK" (receptor activator of NF-kappaB) had not been defined. This term might include OPG (osteoprotegerin). It was clear from document (6) that OPG, despite its activation of alkaline phosphatase, did not lead to osteogenesis (page 619, right-hand column, paragraph 2).

Auxiliary request 1 - novelty

Documents (4), (5), (8), (9), (10) and (11) took away the novelty of claim 1 of auxiliary request 1. Claim 1 of auxiliary request 1 defined the disease in very broad terms. Claim 1 differed from these prior art documents merely in the term "by inducing osteogenesis". The term "by inducing osteogenesis" gave a mechanistic explanation of how the intended treatment of the disease worked. However, in the human body bone resorption and bone formation were balanced and thus closely linked (see document (6), introduction, left-hand column, or document (8), paragraph [0255]). Due to the tight link between bone resorption and bone formation, there was no way for the medical practitioner to apply the actives under consideration in a therapeutically different way. No new teaching was provided, and the clinical situation was not different from the prior art. A new mechanism of action did not automatically lead to a new clinical situation. It was to be stressed that there was no known condition of osteopenia that did not involve resorptive aspects. Some anabolic drugs were known in literature. However, these did not interfere with the RANKL (receptor activator of NF-kappaB ligand) system. There was no evidence on file that an uncoupling of the signal pathways was possible within the RANKL system. To sum up, "by inducing osteogenesis" merely reflected a further mechanism of action or additional physiological effect, but did not lead per se to a new therapeutic application in the context of osteopenia.

Also the same patients were treated. The mere assertion by the patent proprietor that patients suffering from three specific diseases could benefit from the newly discovered mechanism did not change the situation. In fact, these three diseases were treated by anti-resorptive compounds in the prior art.

Auxiliary request 2 - admission

Auxiliary request 2 should not be admitted. Novelty had been one of the main issues throughout the opposition and appeal proceedings. There was thus no reason to submit auxiliary request 2 at this late stage of the proceedings.

Auxiliary request 3 - novelty

The same line of arguments applied as for auxiliary request 1.

Auxiliary request 4 - admission

Auxiliary request 4 should not be admitted, for the same reason as for auxiliary request 2.

X. The arguments of the respondent, insofar as they are relevant for the present decision, may be summarised as follows.

Main request - sufficiency of disclosure

Alkaline phosphatase activity was well known as a marker for osteoblast activity. This was confirmed by the data in the application as filed. In addition to the in vitro data on alkaline phosphatase, the application as filed included in vivo data for peptide D (Example 11). The failure of OPG to lead to an induction of osteogenesis was an isolated failure that did not render claim 1 (which did not include OPG) insufficient. There was no undue burden to establish which compounds were fragments or variants of RANK. Document (11) provided guidance. A skilled person would look to compounds having sequence similarities, in particular since it was known that the folding of the relevant peptides was highly conserved (Figure 1 and page 1526, right-hand column, paragraph 2). A skilled person would not consider OPG to represent a variant of RANK.

Auxiliary request 1 - novelty

The term "by inducing osteogenesis" qualified the intended treatment. It defined how the treatment functioned. The new technical effect of inducing osteogenesis allowed patients to be treated in a new way which represented a new clinical situation. Such a new clinical situation lay in the treatment of metabolic bone disorders associated with osteopenia in which deficient osteogenesis predominated over increased bone resorption (see Table 1 of document (15)) and identified a new sub-group of patients.

In particular, this new technical effect allowed for the treatment of patients who were not adequately treated by anti-resorptives, i.e. patients who needed more than simply the preservation of existing bone mass. According to decision T 1642/06 the group of subjects to be treated did not necessarily need to be different from that of the prior art. Moreover, no distinction between disease states was necessary.

Concerning the arguments of the appellant, the following was stated. There was a link between bone resorption and bone formation, but this homeostatic link could be disrupted under pathological conditions (see documents (15), (5), (7), (8), (10), (13) and (34)). Inhibition of bone formation was of serious concern and there existed patients in need of more than an anti-resorptive treatment (see documents (12), document (15), especially Table 1, referring to OI (osteogenesis imperfecta), Male OP (male osteoporosis) and GIOP (corticosteroid-induced osteoporosis), document (16) and post-published documents (17), (18) and (19))). The present invention broke a paradigm: it showed that uncoupling of bone resorption and bone formation was possible and that drugs that were known as anti-resorptives could be used as anabolic agents (see patent in suit, paragraph [0170]). Thus, the claimed compounds, while still having anti-resorptive properties, could be used in a new way of treatment.

Auxiliary request 2 - admission

Auxiliary request 2 was submitted in reaction to developments during the oral proceedings and should thus be admitted. It differed only in a deletion of subject-matter, and thus represented a simplification and removed disputed points.

Auxiliary request 3 - novelty

The same arguments applied as for auxiliary request 1.

Auxiliary request 4 - admission

In view of the fact that the opposition division had acknowledged a new clinical situation, the findings of the board represented a major change in circumstances. Auxiliary request 4 was closely related to former auxiliary request 3 (filed with the reply to the grounds of appeal), and simplified matters by deleting subject-matter that might have been problematic in the assessment of novelty.

XI. The parties' final requests were as follows.

The appellant requested that the decision under appeal be set aside and that the patent be revoked.

The respondent requested:

-that the appeal be dismissed;

-alternatively, that the patent be maintained on the basis of the set of claims of auxiliary request 1, filed with the reply to the statement of grounds of appeal, auxiliary request 2, filed at the oral proceedings, auxiliary request 3, filed as auxiliary request 2 with the reply to the statement of grounds of appeal, or auxiliary request 4, filed at the oral proceedings.

Reasons for the Decision

1. The appeal is admissible.

2. Admission of documents (31) to (34)

Documents (31) to (34) have been admitted into the proceedings. In view of the outcome of the proceedings, it is not necessary to provide reasons for their admission.

3. Main request - sufficiency of disclosure

3.1 Claim 1 of the main request defines compounds for use in a method referred to in Article 53(c) EPC. The definition of the compounds falling under (i) relies on a functional and a structural part.

3.2 The functional part requires that any of these compounds "acts on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts".

The application as filed contains information on how to determine whether the conditions required by the functional part of the definition of the compounds are fulfilled. In paragraph [0044] (of the A publication) the increase in the alkaline phosphatase activity of the cells and the degree of calcification of the cells is mentioned. Protocols for in vitro tests for these two methods can be found in Examples 1 and 2.

3.3 The structural part includes references to precise structures (peptidic structure known as RANK (or fragment thereof)), compounds comprising certain amino acid sequences (SEQ ID NO: 7 or SEQ ID NO: 16), certain functionally defined structures (antibody or functional fragment thereof having a certain specificity), but also includes compounds of which the structure is merely related to a known structure in an unspecific way, i.e. "a variant of RANK".

Although the term "a variant of RANK" is disclosed in numerous passages of the application as filed, no explanation of what is to be considered a "variant" is given. No compounds representing examples of variants of RANK are listed. The term "variant of RANK" therefore includes any compound that is similar in some way (e.g. in its chemical, physical or functional properties) to RANK. The similarity need not lie in a structural similarity. The application as filed thus contains no guidance as to which compounds are "variants of RANK".

3.4 In the absence of any guidance in the application as filed as to which compounds may be considered to represent "variants of RANK", the skilled person find themselves in a position of having to necessarily resort to arbitrarily selected compounds for use in the in vitro tests establishing the functional requirements (see point 3.2 above).

The use of arbitrarily selected compounds in these tests amounts to trial-and-error experimentation leading to an undue burden.

Consequently, the application does not disclose the subject-matter claimed in the main request in a manner that allows the skilled person to carry out the invention over its whole scope. The disclosure is thus insufficient (Article 83 EPC).

3.5 Further arguments

3.5.1 In the course of the discussion of sufficiency of disclosure, both parties made statements concerning OPG. While it was common ground that OPG did not have the required functionality, there was dispute about the classification of OPG among the compounds defined under point (i) of claim 1.

Whereas the patent in suit describes OPG, in paragraph [0022], as a protein structurally similar to RANK and binding to RANKL, the respondent argued that the skilled person would not consider OPG to be a variant of RANK. No support for this assertion was provided. Nevertheless, it follows that OPG and the analysis of its properties cannot provide any guidance as to the compounds that represent "variants of RANK".

3.5.2 The respondent has furthermore referred to document (11). This document provides the information that the folding and the receptor-ligand contact sites of members of the TNFR and TNF superfamilies are highly conserved. RANK contains key features of the TNFR(I) CRD3 contact point (page 1526, right-hand column, paragraph 2 and Figure 1). According to the respondent, this information would have provided a good starting point for the skilled person looking for variants of RANK.

The board cannot follow this argument. Document (11) cannot and does not provide a teaching for generally identifying substantially all "variants of RANK". Apart from the fact that the term "variant" includes molecules that differ in properties other than similarities in receptor-ligand binding sites, the passage on page 1526, right-hand column, refers to molecular modelling. Molecular modelling is a complex and very specialised technique involving intimate knowledge of various parameters of the system to be modelled. In fact, it can be clearly seen from item A of Figure 1 that TNFR(I), RANK and WP9QY have conserved only 2 amino acids (Trp 107 and Ser 108) in a highlighted sequence of 5 amino acids. TNFR(I) is a peptide of 120 amino acids, RANK contains 134 amino acids and WP9QY merely 9. This shows that considerable additional input is needed to find further compounds. In the absence of any further guidance, the passage of document (11) does not lead the skilled person to "variants of RANK".

4. Auxiliary request 1 - novelty

4.1 The appellant has cited document (11), among other documents, as being novelty-destroying for the subject-matter of claim 1 of auxiliary request 1.

Document (11) discusses the role of WP9QY, a peptide that interferes with RANKL signalling, and its link to bone resorption and bone loss (title, abstract). Data shows that WP9QY inhibits the increased osteoclastogenesis and bone loss induced by ovariectomy or low dietary calcium in mouse models (Figure 7). Osteogenesis is not discussed in document (11).

4.2 There was agreement between the parties that WP9QY was identical to peptide D (a peptide comprising the amino acid sequence represented by SEQ ID NO: 7) and was a compound falling within the scope of claim 1 of auxiliary request 1 (and within the scope of claim 1 of auxiliary request 3). Furthermore, it was common ground that inhibition of bone loss constituted a treatment of bone metabolic disease associated with osteopenia.

There was, however, disagreement between the parties on whether the term "by inducing osteogenesis" was suitable for establishing novelty over document (11). A closer look is thus necessary.

4.3 A new specific use of a known compound in a method of treatment of the human or animal body, which may be a use in a different treatment by therapy of the same illness, may confer novelty on a medical use claim (Article 54(5) EPC in conjunction with Article 53(c) EPC; see also G 2/08, OJ EPO 2010, 456). In the present case, the respondent has relied on two aspects that would constitute such specific use: 1) the term "by inducing osteogenesis" as a technical effect and 2) the sub-group of patients to be treated, distinguished on the basis of this technical effect.

Such aspects may potentially characterise a different, novel and inventive specific use. Therefore it has to be assessed whether these aspects are suitable for establishing such a use under the specific circumstances of the present case.

4.4 The term "by inducing osteogenesis" is thus crucial for the present decision. "By inducing osteogenesis" does not form part of the definition of the disease. Rather, this term qualifies the treatment of the disease. The question arises of whether it is to be considered a mere mechanistic explanation of the treatment, or whether this feature links the treatment to a physiological effect suitable for establishing novelty in the context explained under point 4.3 above.

4.5 It is necessary to take a closer look at the physiological processes and mechanisms involved in the treatment of bone metabolic disease associated with osteopenia by the claimed compounds. Central to these processes and mechanisms are RANK and its ligand RANKL (patent in suit, paragraphs [0009] and [0016]).

According to the patent in suit, RANKL is a ligand for RANK. RANKL is expressed on osteoblasts or cells capable of differentiating into osteoblasts in response to stimulation by bone resorption factors (paragraph [0021]).

This can also be seen from document (4), for example. Document (4) explains that RANKL "is expressed by osteoblasts and their immature precursors and is necessary and sufficient for osteoclastogenesis. RANKL activates its receptor, RANK, which is expressed on osteoclasts and their precursors, thus promoting osteoclast formation and activation and prolonging osteoclast survival by suppressing apoptosis. RANKL is expressed on bone-forming osteoblasts, which indicates that bone resorption and bone formation are coupled through RANKL" (page 490, paragraph bridging left-hand and middle column).

The patent in suit is based on the finding that transmission of reverse signals from RANK to RANKL takes place in addition to transmission of forward signals from RANKL to RANK. The bidirectional signals transmitted between RANKL and RANK control the coupling of bone resorption and formation. By relying on the reverse signals, bone mass can be increased by bone formation (paragraph [0016]).

To sum up, agents interacting at certain points of the osteoblast-RANKL-RANK-osteoclast (or the respective precursors of these cells) signalling pathway may influence the balance (homeostasis) between bone formation and bone resorption.

4.6 The disease to be treated is defined in claim 1 of auxiliary request 1 in broad terms, referring to the physiological state (osteopenia) of the patient to be treated. Osteopenia is a condition in which bone density or bone mass is lower than normal. It includes pre-stages of more severe conditions of bone loss in which only slight changes in bone density (mass) are observed. In Claim 1 no indication is given as to pathophysiology or aetiology.

The respondent has argued that the homeostasis between bone resorption and bone formation would be disrupted under particular pathological conditions leading to a need for a treatment that targets osteogenesis rather than resorption. In this context it has cited several documents.

Document (15) explains that under normal conditions, the bone remodelling process of resorption followed by formation is closely coupled in basic multicellular units and results in no change in bone mass. The coupling between resorption and formation is controlled. Abnormalities in the rate and balance of bone remodelling play a pivotal role in the pathogenesis of bone loss and structural decay (page 154, left-hand column, last paragraph and right-hand column, first full paragraph). Table 1 lists abnormalities and identifies OI (osteogenesis imperfecta), Male OP (male osteoporosis) and GIOP (corticosteroid-induced osteoporosis) as abnormalities showing a decrease in bone formation.

Document (5) states that, for osteopenia and osteoporosis to develop, active destruction must exceed bone formation (uncoupling of bone homeostasis) (page 808, right-hand column, last paragraph).

Document (7) describes, in the context of bone metastases, that, upon treatment with AMGN-0007, which is a recombinant OPG construct, mean BSAP (serum bone-specific alkaline phosphatase; elevated levels of BSAP indicate increased osteoblastic activity) did not decrease to the same extent as urine NTX (N-telopeptide/creatinine; elevated levels of NTX indicate increased bone resorption). BSAP decreases occurred later compared with urine NTX. This was to be expected, since bone formation and resorption are temporally coupled (page 890, right-hand column, paragraph 3).

Document (8) also confirms that bone resorption and formation are intimately linked. The active agent of document (8), alphaOPGL-1, leads to a decrease in bone resorption markers prior to bone formation markers (paragraph [0255]). Document (8) relates to osteopenic disorders.

Document (10) describes that the administration of denosumab to postmenopausal women with low bone mineral density leads to a decrease in bone resorption markers (serum C-telopeptide), followed with a one-month delay by a decrease in bone-specific alkaline phosphatase (a bone formation marker) (page 826, left-hand column, paragraph 3, last sentence).

Document (13) explains that administration of a single dose of OPG to post-menopausal women rapidly decreases bone resorption. A delayed decrease in bone formation marker suggests to the authors of document (13) that OPG does not affect bone formation directly but most likely via an influence on basic multicellular units, the units responsible for bone turnover; the reason for this being that bone resorption normally precedes the coupled bone formation in the usual bone remodelling cycle (page 356, paragraph bridging the columns).

Finally, document (34) states that the most common treatments for osteoporosis are oral bisphosphonates, which act by inhibiting bone resorption. However, since bone remodelling remains coupled, a decrease in bone formation is observed (page 22, last paragraph).

From these documents it can be clearly seen that under pathological conditions bone homeostasis is disturbed. The equilibrium may be shifted towards formation or resorption, possibly due to time-related aspects. However, none of these documents reports a complete disruption of the coupling of bone formation and bone resorption.

4.7 From the paragraph above it can be seen that the term "by inducing osteogenesis" reflects certain mechanistic aspects of the RANKL signalling pathway and thus represents a physiological effect linked to the treatment of osteopenia.

In view of the disclosure of document (11), it is thus necessary to assess whether a treatment that relies on osteogenesis by influencing the RANKL signalling pathway can establish novelty over a treatment that relies on the inhibition of bone resorption involving the same pathway.

4.7.1 A look at the mechanisms of the RANKL signalling pathway underlying the treatment is necessary. An active agent, in the present case, peptide D, is administered to a patient suffering from osteopenia. The active agent acts on its target. There seem to be two ways (see Example 11 of the patent in suit and the disclosure of document (11)), in which the agent acts: forward signalling and reverse signalling. The first way, forward signalling, leads to inhibition of bone resorption. The second way, reverse signalling, leads to osteogenesis. Both ways result in the treatment of the claimed disease. Both ways are heavily controlled in healthy subjects, and there is no indication that this control is completely lost in patients suffering from any form of osteopenia. Therefore, both ways will occur inseparably in any patient.

Consequently, the reference to "inducing osteogenesis", while indicating a physiological effect, does not lead to a situation in which forward signalling (leading to the inhibition of resorption on which document (11) relies) ceases to be of relevance.

4.7.2 The respondent has referred to two decisions of the Boards of Appeal, T 1642/06 and T 836/01.

T 1642/06 relates to the treatment of cancer by a sigma receptor ligand. The board came to the conclusion that the claimed use represented a further and different therapeutic use from that disclosed in the prior art. Whereas the prior art relied on inducing tumour cell division cycle arrest and/or apoptosis, i.e. a direct effect on tumour cells, the patent under consideration concerned an indirect influence of the active agent on the tumour cells via the inhibition of the neovascularisation of tumours.

In T 836/01, the board found that the treatment under consideration relied on a different technical effect from the one disclosed in the prior art. Whereas the prior art disclosed the use of the active agent for the purpose of activating mature lymphoid cells exerting cytolytic T cell activity on cancer cells, i.e. an indirect effect on cancer cells, the claimed subject matter defined a direct influence on cell growth and differentiation of the cancer cells. This different effect identified a new clinical situation and related sub-group of patients.

The facts of both of these decisions differ from the present situation in that two unrelated mechanisms of action were under consideration. In contrast, the present situation concerns effects based on mechanisms of action that are closely coupled.

4.8 In conclusion, the board considers that the patent in suit provides information on a new mechanism of action of peptide D, one of the claimed compounds. This mechanism of action is closely and inseparably linked to the known activity of peptide D of inhibiting bone resorption. No evidence of complete uncoupling of these two activities has been shown. The claimed use cannot be distinguished from the known use of peptide D. The technical effect of inducing osteogenesis is therefore not apt to constitute a new specific use in the sense of point 4.3 above.

4.9 Further arguments

4.9.1 The respondent has argued that a treatment relying on osteogenesis allowed for the treatment of patients who were not adequately treated by anti-resorptives, i.e. patients who needed more than simply the preservation of existing bone mass. In this context it has referred to documents (12), (15), (16), (17), (18) and (19).

Document (12) explains that it is believed that dysfunctional osteoblasts are the cause of cortisone-induced osteoporosis. Therapies relying on anabolic treatment should be developed for this type of osteopenia. It goes on to state that in recent years new therapies have been proposed using drugs that could decrease the prevalence of apoptosis on osteoblasts, possibly increasing their proliferation and/or functional activity (page 1016, paragraph bridging the columns).

The relevant parts of the disclosure of document (15) can be found under point 4.6 above.

Document (16) states that bone histomorphometry has confirmed that the mechanism of action of anabolic agents is fundamentally different from that of anticatabolic drugs. Rather than reducing the activation frequency of bone remodelling, anabolic agents increase it, leading to a positive bone balance. Therefore, anabolic agents are able to improve, rather than simply preserve cancellous and cortical bone microarchitecture (paragraph bridging pages 455 and 456). The RANKL-RANK signalling pathway is not mentioned.

The post-published documents (17), (18) and (19) have no relevance for the present decision as they cannot give insight into the understanding of the skilled person at the effective date of the patent in suit, or provide evidence of how document (11) is to be read. None of these documents discusses compounds related to the RANKL-RANK signalling pathway.

It is clear from documents (12), (15) and (16) that pathophysiological situations exist in which it may be preferable to rely on an increase in bone formation for treatment. However, the actives under consideration, which are not discussed in any of these documents, will nevertheless perform their homeostatically (or at least partially) controlled functions. Thus, they cannot act as mere anabolic agents, performing only or predominantly only one of their modes/ways of action.

4.9.2 In the context of bone homeostasis and its uncoupling, the respondent has referred to paragraph [0170] of the patent in suit. There, four anti-RANKL antibodies are discussed, of which two (antibodies #22 and B) neutralise the osteoclast differentiation by RANKL, one (antibody B) having a proliferative effect on osteoblasts. Four antibodies, including antibody #22 (with no proliferative effect on osteoblasts) stimulate osteoblast differentiation, including neutralising and non-neutralising antibodies. Of two further anti-RANKL antibodies (7H12 and 10C11), one stimulates osteoblast differentiation (10C11). According to the respondent, this showed that uncoupling was possible.

The board cannot accept this argument, in particular in respect of the situation under consideration, which concerns the activity of peptide D. To begin with, bone homeostasis in the bone remodelling cycle has temporal aspects (see documents (7), (8), (10) and (13) discussed above). It is not clear how such temporal aspects could be reflected in the experiments referred to in paragraph [0170], which were completed within a relatively short time (in relation to the bone remodelling cycle). Furthermore, paragraph [0170] deals with very specific anti-RANKL antibodies. The specific nature of the situation in paragraph [0170] is underlined by the need to differentiate between proliferative effects and the stimulation of differentiation. It is thus unclear whether these effects, and if so which ones, are relevant for peptide D.

4.9.3 To sum up, the technical effect of inducing osteogenesis is closely and inseparably linked to the known effects of the compound under consideration. In consequence, the terms "by inducing osteogenesis" cannot define the inherent presence of a new (sub) group of patients. Such a group of patients is also not explicitly mentioned in claim 1 of auxiliary request 1. Therefore, the technical effect of inducing osteogenesis is not suitable for establishing a new specific use in the treatment of osteopenia.

4.10 In view of the above, the board concludes that the subject-matter of claim 1 of auxiliary request 1 relates to the same compound for use in the same treatment of the same condition as document (11). The subject-matter of claim 1 of auxiliary request 1 lacks novelty (Article 54 EPC).

5. Admission of auxiliary request 2

Auxiliary request 2 was filed at a very advanced stage of the appeal proceedings, namely during the oral proceedings before the board, after the discussion on the novelty of auxiliary request 1 had been completed. No new aspects were raised during oral proceedings before the board beyond those already addressed during the written phase of the appeal proceedings. Therefore, the filing of auxiliary request 2 cannot be seen as a timely and appropriate reaction to new developments during oral proceedings and thus as a reaction to exceptional circumstances.

The fact that claim 1 of auxiliary request 2 differs from claim 1 of auxiliary request 1 merely in the deletion of features does not change the situation. The patent proprietor is the party that is solely responsible for determining the text of the patent (see Article 113(2) EPC). It is obliged to submit amendments or possible fall-back positions. For reasons of procedural economy and fairness to the other party this must be done at the earliest possible opportunity. The nature of the amendments is not decisive for the application of Article 13(2) RPBA.

Auxiliary request 2 is not admitted into the proceedings, in accordance with Article 13(2) RPBA.

6. Auxiliary request 3 - novelty

Claim 1 of auxiliary request 3 lacks novelty for the same reasons as those given for claim 1 of auxiliary request 1; see point 4 above (Article 54 EPC).

7. Admission of auxiliary request 4

Auxiliary request 4 was filed at a very advanced stage of the appeal proceedings, namely towards the end of the oral proceedings before the board, after a conclusion had been reached on the novelty of auxiliary request 3. No new aspects were raised during oral proceedings before the board beyond those already addressed during the written phase of the appeal proceedings. Therefore, the filing of auxiliary request 4 cannot be seen as a timely and appropriate reaction to new developments during oral proceedings and thus as a reaction to exceptional circumstances.

The fact that a board might take a different view, on the basis of arguments presented by a party, from the department whose decision is appealed does not represent exceptional circumstances as it is one of the two possibilities.

Auxiliary request 4 is not admitted into the proceedings in accordance with Article 13(2) RPBA.

Entscheidungsformel

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

Footer - Service & support
  • Unterstützung
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
    • FAQ
    • Veröffentlichungen
    • Verfahrensbezogene Mitteilungen
    • Kontakt
    • Aboverwaltung
    • Offizielle Feiertage
    • Glossar
Footer - More links
  • Jobs & Karriere
  • Pressezentrum
  • Single Access Portal
  • Beschaffung
  • Beschwerdekammern
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Impressum
  • Nutzungsbedingungen
  • Datenschutz
  • Barrierefreiheit